Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Corrección del autor: Programas de transcripción de TIL específico de neoantigenos en cánceres de pulmón tratados con anti-PD-1

Justina X Caushi ^1,2,3, Jiajia Zhang ^1,2,3, Zhicheng Ji ^4,5

¹Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
²The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA.
³Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
⁴Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
⁵Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
⁶Ludwig Center and Howard Hughes Medical Institute at Johns Hopkins, Baltimore, MD, USA.
⁷Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
⁸Immunitrack, Copenhagen, Denmark.
⁹Ontario Institute for Cancer Research, Queens University, Kingston, Ontario, Canada.
¹⁰Beaumont Hospital Dublin, RCSI University of Medicine and Health Science, Dublin, Ireland.
¹¹Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.
¹²Georgetown Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA.
¹³The Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁴Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁵Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu.
¹⁶The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu.
¹⁷Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu.
¹⁸Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. hji@jhu.edu.
¹⁹Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu.
²⁰The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu.
²¹Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu.
²²Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu.
²³The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu.
²⁴Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu.

⁰Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.

Nature +

|

5 de octubre de 2021

Resumen

No abstract available on PubMed

Videos de Conceptos Relacionados

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.